First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial - 30/06/16
, Anna-Maria Fink, MD a, Jasmin Bahlo, PhD a, Raymonde Busch, Dipl Math b, Gabor Kovacs, MD a, Christian Maurer, MD a, Elisabeth Lange, MD c, Hubert Köppler, ProfMD d, Michael Kiehl, ProfMD e, Martin Sökler, MD f, Rudolf Schlag, MD g, Ursula Vehling-Kaiser, MD h, Georg Köchling, MD i, Christoph Plöger, MD j, Michael Gregor, MD k, Torben Plesner, MD l, Marek Trneny, ProfMD m, Kirsten Fischer, MD a, Harmut Döhner, ProfMD n, Michael Kneba, ProfMD o, Clemens-Martin Wendtner, ProfMD p, Wolfram Klapper, ProfMD q, Karl-Anton Kreuzer, ProfMD a, Stephan Stilgenbauer, ProfMD n, Sebastian Böttcher, MD o, Michael Hallek, ProfMD a, ron behalf of an
international group of investigators
theGerman CLL Study Group (GCLLSG)
Summary |
Background |
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab is the standard therapy for physically fit patients with advanced chronic lymphocytic leukaemia. This international phase 3 study compared the efficacy and tolerance of the standard therapy with a potentially less toxic combination consisting of bendamustine and rituximab.
Methods |
Treatment-naive fit patients with chronic lymphocytic leukaemia (aged 33–81 years) without del(17p) were enrolled after undergoing a central screening process. Patients were randomly assigned (1:1) with a computer-generated randomisation list using randomly permuted blocks with a block size of eight and were stratified according to participating country and Binet stage. Patients were allocated to receive six cycles of intravenous fludarabine (25 mg/m2 per day) and cyclophosphamide (250 mg/m2 per day) for the first 3 days or to intravenous bendamustine (90 mg/m2 per day) for the first 2 days of each cycle. Rituximab 375 mg/m2 was given intravenously in both groups on day 0 of cycle 1 and subsequently was given at 500 mg/m2 during the next five cycles on day 1. The primary endpoint was progression-free survival with the objective to assess non-inferiority of bendamustine and rituximab to the standard therapy. We aimed to show that the 2-year progression-free survival with bendamustine and rituximab was not 67·5% or less with a corresponding non-inferiority margin of 1·388 for the hazard ratio (HR) based on the 90·4% CI. The final analysis was done by intention to treat. The study is registered with ClinicalTrials.gov, number NCT%2000769522.
Findings |
688 patients were recruited between Oct 2, 2008, and July 11, 2011, of which 564 patients who met inclusion criteria were randomly assigned. 561 patients were included in the intention-to-treat population: 282 patients in the fludarabine, cyclophosphamide, and rituximab group and 279 in the bendamustine and rituximab group. After a median observation time of 37·1 months (IQR 31·0–45·5) median progression-free survival was 41·7 months (95% CI 34·9–45·3) with bendamustine and rituximab and 55·2 months (95% CI not evaluable) with fludarabine, cyclophosphamide, and rituximab (HR 1·643, 90·4% CI 1·308–2·064). As the upper limit of the 90·4% CI was greater than 1·388 the null hypothesis for the corresponding non-inferiority hypothesis was not rejected. Severe neutropenia and infections were more frequently observed with fludarabine, cyclophosphamide, and rituximab (235 [84%] of 279 vs 164 [59%] of 278, and 109 [39%] vs 69 [25%], respectively) during the study. The increased frequency of infectious complications with fludarabine, cyclophosphamide, and rituximab was more pronounced in patients older than 65 years.
Interpretation |
The combination of fludarabine, cyclophosphamide, and rituximab remains the standard front-line therapy in fit patients with chronic lymphocytic leukaemia, but bendamustine and rituximab is associated with less toxic effects.
Funding |
Roche Pharma AG, Mundipharma, German Federal Ministry of Education and Research.
Le texte complet de cet article est disponible en PDF.Plan
Vol 17 - N° 7
P. 928-942 - juillet 2016 Retour au numéro
Article précédent
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- Toni K Choueiri, Bernard Escudier, Thomas Powles, Nizar M Tannir, Paul N Mainwaring, Brian I Rini, Hans J Hammers, Frede Donskov, Bruce J Roth, Katriina Peltola, Jae Lyun Lee, Daniel Y C Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N Sternberg, David F McDermott, Dana T Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas E Hutson, Sumanta Pal, Robert J Motzer, METEOR investigators
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- Jeffrey S Weber, Geoff Gibney, Ryan J Sullivan, Jeffrey A Sosman, Craig L Slingluff, Donald P Lawrence, Theodore F Logan, Lynn M Schuchter, Suresh Nair, Leslie Fecher, Elizabeth I Buchbinder, Elmer Berghorn, Mary Ruisi, George Kong, Joel Jiang, Christine Horak, F Stephen Hodi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?